Show simple item record

dc.contributor.authorDe Rycker, Manu
dc.contributor.authorHorn, David
dc.contributor.authorAldridge, Bree
dc.contributor.authorAmewu, Richard K
dc.contributor.authorBarry, Clifton E
dc.contributor.authorBuckner, Frederick S
dc.contributor.authorCook, Sarah
dc.contributor.authorFerguson, Michael A J
dc.contributor.authorGobeau, Nathalie
dc.contributor.authorHerrmann, Jennifer
dc.contributor.authorHerrling, Paul
dc.contributor.authorHope, William
dc.contributor.authorKeiser, Jennifer
dc.contributor.authorLafuente-Monasterio, Maria Jose
dc.contributor.authorLeeson, Paul D
dc.contributor.authorLeroy, Didier
dc.contributor.authorManjunatha, Ujjini H
dc.contributor.authorMcCarthy, James
dc.contributor.authorMiles, Timothy J
dc.contributor.authorMizrahi, Valerie
dc.contributor.authorMoshynets, Olena
dc.contributor.authorNiles, Jacquin
dc.contributor.authorOverington, John P
dc.contributor.authorPottage, John
dc.contributor.authorRao, Srinivasa P S
dc.contributor.authorRead, Kevin D
dc.contributor.authorRibeiro, Isabela
dc.contributor.authorSilver, Lynn L
dc.contributor.authorSouthern, Jen
dc.contributor.authorSpangenberg, Thomas
dc.contributor.authorSundar, Shyam
dc.contributor.authorTaylor, Caitlin
dc.contributor.authorVan Voorhis, Wes
dc.contributor.authorWhite, Nicholas J
dc.contributor.authorWyllie, Susan
dc.contributor.authorWyatt, Paul G
dc.contributor.authorGilbert, Ian H
dc.date.accessioned2020-01-03T09:29:30Z
dc.date.available2020-01-03T09:29:30Z
dc.date.issued2019-12-06
dc.identifier.citationACS Infect Dis. 2019 Dec 6. doi: 10.1021/acsinfecdis.9b00371.en_US
dc.identifier.issn2373-8227
dc.identifier.pmid31808676
dc.identifier.doi10.1021/acsinfecdis.9b00371
dc.identifier.urihttp://hdl.handle.net/10033/622056
dc.description.abstractIn May 2019, the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering new medicines for infectious diseases and a particular focus on diseases affecting Low and Middle Income Countries. There is an urgent need for new drugs to treat most infectious diseases. We were keen to see if there were lessons that we could learn across different disease areas and between the preclinical and clinical phases with the aim of exploring how we can improve and speed up the drug discovery, translational, and clinical development processes. We started with an introductory session on the current situation and then worked backward from clinical development to combination therapy, pharmacokinetic/pharmacodynamic (PK/PD) studies, drug discovery pathways, and new starting points and targets. This Viewpoint aims to capture some of the learnings.en_US
dc.language.isoenen_US
dc.publisherAmerican Society for Chemistryen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleSetting Our Sights on Infectious Diseases.en_US
dc.typeArticleen_US
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalACS Infectious Diseasesen_US
refterms.dateFOA2020-01-03T09:29:31Z
dc.source.journaltitleACS infectious diseases


Files in this item

Thumbnail
Name:
De Rycker et al.pdf
Size:
288.8Kb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International